Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer's dementia.

导出 OA

翻译打印收藏纠错

作者： Marwan N,Sabbagh ^[1] ; Kewei,Chen ^[2] ; Joseph,Rogers ^[3] ; Adam S,Fleisher ^[4] ; Carolyn,Liebsack ^[5] ; Dan,Bandy ^[4] ; Christine,Belden ^[5] ; Hillary,Protas ^[4] ; Pradeep,Thiyyagura ^[4] ; Xiaofen,Liu ^[4] ; Auttawut,Roontiva ^[4] ; Ji,Luo ^[4] ; Sandra,Jacobson ^[5] ; Michael,Malek-Ahmadi ^[5] ; Jessica,Powell ^[5] ; Eric M,Reiman ^[6]

作者单位： Banner Sun Health Research Institute, Sun City, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA; College of Medicine, University of Arizona, Phoenix, AZ, USA. Electronic address: marwan.sabbagh@bannerhealth.com. ^[1] Arizona Alzheimer's Consortium, Phoenix, AZ, USA; Banner Alzheimer's Institute, Phoenix, AZ, USA; Arizona State University, Tempe, AZ, USA. ^[2] SRI International, Palo Alto, CA, USA. ^[3] Arizona Alzheimer's Consortium, Phoenix, AZ, USA; Banner Alzheimer's Institute, Phoenix, AZ, USA. ^[4] Banner Sun Health Research Institute, Sun City, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA. ^[5] Arizona Alzheimer's Consortium, Phoenix, AZ, USA; College of Medicine, University of Arizona, Phoenix, AZ, USA; Banner Alzheimer's Institute, Phoenix, AZ, USA; Translational Genomics Research Institute, Phoenix, AZ, USA. ^[6]

关键词 Alzheimer's disease Dementia Down syndrome FDG-PET Florbetapir Imaging PET